ClonoSEQ

DEVICE3 trials

Sponsors

Adaptive Biotechnologies, Washington University School of Medicine, Danielle Wallace

Conditions

Diffuse Large B Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Follicular LymphomaMantle Cell LymphomaMultiple Myeloma

Phase 2

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

RecruitingNCT06483100

Washington University School of MedicineMultiple Myeloma

Start: 2024-12-20End: 2032-06-30Target: 65Updated: 2026-08-06

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

RecruitingNCT06828991

Danielle WallaceDiffuse Large B-Cell Lymphoma (DLBCL)

Start: 2025-09-04End: 2030-04-30Target: 40Updated: 2025-10-17

Unknown Phase

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

RecruitingNCT05255354

Adaptive BiotechnologiesDiffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

Start: 2022-06-01End: 2026-12-31Target: 300Updated: 2024-08-22